Results 91 to 100 of about 581 (108)

Expert opinion on sonidegib efficacy, safety and tolerability

Expert Opinion on Drug Safety, 2021
Introduction: Hedgehog inhibitors are an alternative treatment option for patients with advanced BCCs not eligible for standard therapies due to lack of efficacy, high recurrence risk, and high-rate morbidity.
Alessia Villani, Sonia Sofía Ocampo-Garza, Aimilios Lallas   +2 more
exaly   +2 more sources

Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers

Cancer Chemotherapy and Pharmacology, 2014
Purpose: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.
Markus Zollinger, Hounayda Bauly
exaly   +2 more sources

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data [PDF]

Cancers, 2023
Basal cell carcinoma (BCC) represents the most common skin cancer and locally advanced BCC (laBCC) refers to an aggressive, large, infiltrative BCC that cannot be treated by surgery or radiotherapy.
Gianluca Nazzaro, Emanuela Passoni, Giada A Beltramini   +2 more
exaly   +2 more sources

Treatment of Advanced Basal Cell Carcinoma with Sonidegib: Perspective from the 30-Month Update of the BOLT Trial

Future Oncology, 2018
Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy.
Heng-Huan Lee, Michael R Migden
exaly   +2 more sources

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas [PDF]

OncoTargets and Therapy, 2017
The Hedgehog (Hh) pathway is critical for cell differentiation, tissue polarity, and stem cell maintenance during embryonic development, but is silent in adult tissues under normal conditions. However, aberrant Hh signaling activation has been implicated
Sachin Jain, Jingwu Xie
exaly   +2 more sources

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

Investigational New Drugs, 2017
Purpose To establish a recommended phase II dose (RP2D) for the oral smoothened inhibitor sonidegib in combination with paclitaxel; secondary objectives include evaluation of safety, tolerability, markers of Hedgehog (Hh) signaling and preliminary ...
Anastasios Stathis, Gaia Griguolo, Piera Gargiulo   +2 more
exaly   +2 more sources

Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study [PDF]

Cancers
Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome (GS), is a genetic disorder characterized by the development of multiple cutaneous BCCs due to mutations in the hedgehog signaling pathway. The use of hedgehog pathway inhibitors&
Gianluca Nazzaro, Emanuela Passoni, Nerina Denaro   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Sonidegib potentiates the cancer cells’ sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 and

Biochemical Pharmacology, 2022
Jakub Hofman, Dimitrios Vagiannis, Youssif Budagaga   +2 more
exaly  

The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours

British Journal of Clinical Pharmacology, 2021
Anthony J Olszanski, Ulka Vaishampayan, Vincent Chung   +2 more
exaly  

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma

Actas Dermo-sifiliográficas, 2021
Rafael Botella, Susana Puig, B Llombart
exaly